MS Coalition seeks participants for secondary progressive survey

January 24, 2019
The MS Coalition is seeking people with secondary progressive multiple sclerosis for a review of disease-modifying therapies.

Institute for Clinical and Economic Review is currently conducting a review of disease-modifying therapies for secondary progressive MS. Insurers may use ICER recommendations to develop or change their approved drug lists, which could potentially improve or restrict access to MS medications for people living with MS. To ensure that people living with MS have direct input into their analysis of the use and effectiveness of disease-modifying therapies, the MS Coalition contacted ICER.

A survey has been developed to gain patient input into secondary progressive MS. Participant input is important and experience matters. The survey may be accessed by using the survey link:

www.surveygizmo.com/s3/4781016/MS-Coalition-ICER-SPMS-Survey

The survey link will be active through Jan. 28. The survey is anonymous and voluntary. If you have any questions email support@msfocus.org.  

MS Focus is a member of the MS Coalition which is working with the Institute for Clinical and Economic Review. ICER is an organization that conducts clinical and cost effectiveness analysis of new medicines. 

The MS Coalition is a not-for-profit organization through which nine independent MS organizations collaborate to improve the quality of life for those living with or affected by MS. Together, we strive to address advocacy issues that affect access to care, develop and disseminate needed informational and programmatic resources for the MS community and leverage our collective strength to promote greater funding opportunities for MS research.

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Study uncovers potential risks of common MS treatment


Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more

BMI, but not age at puberty, tied to MS risk

March 22, 2019

If so, this could be another important reason for public health initiatives to focus on lowering obesity rates.
Learn more